Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

BIOLOGICAL(8)
MIXED(4)
DRUG(3)
Assigned Interventions CD19/BCMA CAR T-cells
4 trials
early_phase_1
zhejiang-university
Cyclophosphamid
1 trial
phase_1
zhejiang-university
Autologous hematopoietic stem cell transplantation combined with CD19 CAR-T cells
1 trial
early_phase_1
zhejiang-university
CLL1 CAR T-cells
1 trial
early_phase_1
zhejiang-university
Rituximab
1 trial
phase_1
zhejiang-university
CD19/BCMA CAR T-cells
1 trial
early_phase_1
zhejiang-university
CD7 CAR T-cells
1 trial
early_phase_1
zhejiang-university
CD38 CAR T-cells
1 trial
early_phase_1
zhejiang-university

+4 more interventions

12 unique interventions3 categories

Analytics

Trial Phases

Phase 12

Trial Status

Recruiting1
Other10

Role Distribution

Principal Investigator11
PI Rate100%

Activity Timeline

Clinical Trials (11)

NCT06750133Phase 1Recruiting
Universal CNK-UT Therapy for Refractory aGVHD
Acute Graft-versus-Host Disease
PrincipalinvestigatorStart date: 2024-12-14
NCT05379647Phase 1Unknown
Natural Killer (NK) Cell Therapy for B-Cell Malignancies
B-cell Acute Lymphoblastic LeukemiaB-cell Lymphoma
PrincipalinvestigatorStart date: 2021-11-04
NCT05085444Early Phase 1Unknown
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma
Autoimmune DiseasesScleroderma
PrincipalinvestigatorStart date: 2021-10-08
NCT05263817Early Phase 1Unknown
A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis
AmyloidosisAutoimmune Hemolytic AnemiaPOEMS Syndrome+1 more
PrincipalinvestigatorStart date: 2021-10-08
NCT05030779Early Phase 1Unknown
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus
Autoimmune DiseasesSystemic Lupus Erythematosus
Principalinvestigator
NCT05085418Early Phase 1Unknown
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Immune Nephritis
Autoimmune DiseasesImmune NephritisLupus Nephritis
Principalinvestigator
NCT05085431Early Phase 1Unknown
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome
Autoimmune DiseasesSjogren's Syndrome
Principalinvestigator
NCT05239676Early Phase 1Unknown
Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant Lymphoma
Lymphoma
Principalinvestigator
NCT05239689Early Phase 1Unknown
Clinical Study of CD38 CAR-T Cells in the Treatment of Hematological Malignancies
AML
Principalinvestigator
NCT05239702Early Phase 1Unknown
Clinical Study of Targeting CD7 CAR-T Cells in the Treatment of Autoimmune Diseases
Autoimmune DiseasesCrohn DiseaseDermatomyositis+2 more
Principalinvestigator

Showing 10 of 11 trials

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Sabine Hazan, MD

ProgenaBiome

Related
41 trials

Shared therapeutic areas:

Crohn DiseaseColitis, UlcerativeLupus Erythematosus, Systemic
Similarity Score5%

Michael B Gill

Power Life Sciences Inc.

Related
105 trials

Shared therapeutic areas:

LymphomaSclerodermaColitis, Ulcerative
Similarity Score5%

Areej El-Jawahri, MD

Massachusetts General Hospital

Related
21 trials

Shared therapeutic areas:

AMLLymphoma
Similarity Score3%

Mary Horowitz, MD

Center for International Blood and Marrow Transplant Research

Related
24 trials

Shared therapeutic areas:

LymphomaLymphoma, B-Cell
Similarity Score3%

Kazuoki Kondo, MD

Tanabe Pharma Corporation

Related
20 trials

Shared therapeutic areas:

Crohn DiseaseLupus Erythematosus, Systemic
Similarity Score3%

Helen Heslop, MD

Baylor College of Medicine

Related
17 trials

Shared therapeutic areas:

Lymphoma, B-CellLymphoma
Similarity Score3%

Lizhi Niu, PhD

Fuda Cancer Hospital

Related
31 trials

Shared therapeutic areas:

Lymphoma, B-Cell
Similarity Score2%

Brigitte C Widemann, M.D.

National Cancer Institute (NCI)

Related
19 trials

Shared therapeutic areas:

Lymphoma
Similarity Score2%

Hamid Gourabi, PhD

head of Royan Institute

Related
52 trials

Shared therapeutic areas:

Crohn Disease
Similarity Score2%

emilie garrido pradalie

APHM

Related
35 trials

Shared therapeutic areas:

Crohn Disease
Similarity Score2%

Publications (0)

No publications found for this investigator.

Clinical Trials (11)

Showing 11 of 11 trials

NCT06750133Phase 1PrincipalInvestigator

Universal CNK-UT Therapy for Refractory aGVHD

Acute Graft-versus-Host Disease
Recruiting
NCT05379647Phase 1PrincipalInvestigator

Natural Killer (NK) Cell Therapy for B-Cell Malignancies

B-cell Acute Lymphoblastic LeukemiaB-cell Lymphoma
Unknown
NCT05085444Early Phase 1PrincipalInvestigator

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma

Autoimmune DiseasesScleroderma
Unknown
NCT05263817Early Phase 1PrincipalInvestigator

A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis

AmyloidosisAutoimmune Hemolytic AnemiaPOEMS Syndrome+1 more
Unknown
NCT05030779Early Phase 1PrincipalInvestigator

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus

Autoimmune DiseasesSystemic Lupus Erythematosus
Unknown
NCT05085418Early Phase 1PrincipalInvestigator

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Immune Nephritis

Autoimmune DiseasesImmune NephritisLupus Nephritis
Unknown
NCT05085431Early Phase 1PrincipalInvestigator

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome

Autoimmune DiseasesSjogren's Syndrome
Unknown
NCT05239676Early Phase 1PrincipalInvestigator

Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant Lymphoma

Lymphoma
Unknown
NCT05239689Early Phase 1PrincipalInvestigator

Clinical Study of CD38 CAR-T Cells in the Treatment of Hematological Malignancies

AML
Unknown
NCT05239702Early Phase 1PrincipalInvestigator

Clinical Study of Targeting CD7 CAR-T Cells in the Treatment of Autoimmune Diseases

Autoimmune DiseasesCrohn DiseaseDermatomyositis+2 more
Unknown
NCT05252572Early Phase 1PrincipalInvestigator

Clinical Study of CLL1 CAR-T Cells in the Treatment of Hematological Malignancies

AML
Unknown

All 11 trials loaded